Immortal Dragons, a longevity fund valued at $40 million, has declared its strategic investment in Unlimited Bio, a biotechnology firm focused on developing combinatorial therapies aimed at tackling the complex nature of aging. This announcement was made on October 22, 2025, in Singapore, highlighting the growing interest and investment in the field of anti-aging research.
The investment signifies a commitment to advancing scientific approaches that address the multi-system challenges associated with aging. Unlimited Bio is known for its innovative strategies in biotechnology, particularly in creating therapies that may mitigate the effects of aging across multiple biological systems.
This partnership is expected to enhance the development of new therapies that could potentially transform the landscape of age-related health issues. With aging populations worldwide, the demand for effective anti-aging solutions is more pressing than ever, making this investment timely and strategic.
The collaboration between Immortal Dragons and Unlimited Bio underscores the importance of combining resources and expertise to push the boundaries of what is possible in longevity science.
